Treatment Information

Back

Breast Cancer treatment details. Chemotherapy, Biologic therapy.

The Ottawa Hospital Cancer Centre, Ottawa, Canada.

Survival: monthsCountry:Canada
Toxiciy Grade:5City/State/Province:Ottawa
Treatments:Chemotherapy, Biologic therapyHospital:The Ottawa Hospital Cancer Centre
Drugs:Journal:Link
Date:Sep 2010

Description:

Patients:
This study involved women with metastatic or recurrent breast cancer who had previously received chemotherapy. Patients were divided into 2 treatment groups. Group 1 consisted of 42 women with a median age of 55.6 years. The median age in group 2 was 53.9 years.

Treatment:
Patients in group 1 were treated with a combination of the chemotherapy agent capecitabine and a biologic therapy enzastaurin, which is a serine/threonine kinase inhibitor that blocks cancer cell growth and causes cell death.

Patients in group 2 received chemotherapy with capecitabine along with a placebo.

Toxicities:
The highest toxicity grade reported was grade 5, due to 2 treatment-related deaths in each treatment group. Other reported toxicities included diarrhea, hand-foot skin reactions, nausea, and vomiting.

Results:
Media overall survival in group 1 was 9.9 months (range of 0.6 to 20.8 months). For group 2 the median overall survival was 14.9 months (range of 0.9 to 19.3 months).

Support:
This study was supported by Eli Lilly, makers of enzastaurin.

Correspondence: Dr. Mark Clemons; email: [email protected]



Back